Log in

Relevant bibliographies by topics / Transdermal adhesive / Journal articles

To see the other types of publications on this topic, follow the link: Transdermal adhesive.

Journal articles on the topic 'Transdermal adhesive'

Author: Grafiati

Published: 4 June 2021

Last updated: 4 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Transdermal adhesive.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Silverman, Ronald P., Jennifer Elisseeff, David Passaretti, Wynne Huang, Mark A. Randolph, and Michael J. Yaremchuk. "Transdermal Photopolymerized Adhesive for Seroma Prevention." Plastic and Reconstructive Surgery 103, no. 2 (February 1999): 531–35. http://dx.doi.org/10.1097/00006534-199902000-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Arunprasert, Kwanputtha, Chaiyakarn Pornpitchanarong, Theerasak Rojanarata, Tanasait Ngawhirunpat, Praneet Opanasopit, Porawan Aumklad, and Prasopchai Patrojanasophon. "Development and Evaluation of Novel Water-Based Drug-in-Adhesive Patches for the Transdermal Delivery of Ketoprofen." Pharmaceutics 13, no. 6 (May 25, 2021): 789. http://dx.doi.org/10.3390/pharmaceutics13060789.

Full text

Abstract:

The objective of this study was to develop novel water-based drug-in-adhesive pressure-sensitive adhesives (PSAs) patches for the transdermal delivery of ketoprofen, employing poly(N-vinylpyrrolidone-co-acrylic acid) copolymer (PVPAA) and poly(methyl vinyl ether-alt-maleic anhydride) (PMVEMA) as the main components. The polymers were crosslinked with tartaric acid and dihydroxyaluminium aminoacetate using various polymer ratios. Ketoprofen was incorporated into the PVPAA/PMVEMA PSAs during the patch preparation. The physicochemical properties, adhesive properties, drug content, release profile, and skin permeation of the patches were examined. Moreover, the in vivo skin irritation and skin adhesion performance in human volunteers were evaluated. The patches prepared at a weight ratio of PVPAA/PMVEMA of 1:1 presented the highest tacking strength, with desirable peeling characteristics. The ketoprofen-loaded PVPAA/PMVEMA patches exhibited superior adhesive properties, compared to the commercial patches, because the former showed an appropriate crosslinking and hydrating status with the aid of a metal coordination complex. Besides, the permeated flux of ketoprofen through the porcine skin of the ketoprofen-loaded PVPAA/PMVEMA patches (4.77 ± 1.00 µg/cm2/h) was comparable to that of the commercial patch (4.33 ± 0.80 µg/cm2/h). In human studies, the PVPAA/PMVEMA patches exhibited a better skin adhesion performance, compared with the commercial patches, without skin irritation. In addition, the patches were stable for 6 months. Therefore, these novel water-based PSAs may be a potential adhesive for preparing drug-in-adhesive patches.

APA, Harvard, Vancouver, ISO, and other styles

3

Nair, Gupta, Al-Dhubiab, Jacob, Shinu, Shah, Morsy, et al. "Effective Therapeutic Delivery and Bioavailability Enhancement of Pioglitazone Using Drug in Adhesive Transdermal Patch." Pharmaceutics 11, no. 7 (July 23, 2019): 359. http://dx.doi.org/10.3390/pharmaceutics11070359.

Full text

Abstract:

The administration of pioglitazone as an oral therapy is restricted due to various challenges. The aim of the current investigation was to evaluate the suitability of pioglitazone in adhesive transdermal patch as an alternative delivery system, in order to improve therapeutic delivery. Drug in adhesive pioglitazone (2% w/w) transdermal patch were optimized for drug release, suitable adhesive, and skin permeation enhancer. The selected patch was examined for drug-loading capacity and the patch with greater pioglitazone (6% w/w) was evaluated in rat models. The release of pioglitazone was influenced by the tested adhesive and was shown to be significantly higher (p < 0.001) with patch, prepared using Duro-Tak 87-2516. The ex vivo permeation results substantiate the release data as a greater transdermal flux (15.67 ± 2.35 µg/cm2/h) was demonstrated in patch fabricated with Duro-Tak 87-2516. Skin penetration enhancers promoted the ex vivo transdermal delivery of pioglitazone, and was ~2 folds (p < 0.0001) higher with propylene glycol, as compared to patch without enhancer. The maximum solubility of pioglitazone in Duro-Tak 87-2516 was found to be 6% w/w. Increasing the drug content in patch enhanced the transdermal flux and was highest when the pioglitazone level was 6% w/w (72.68 ± 5.76 µg/cm2/h). In vivo pharmacokinetic data demonstrate that the AUC0-α in transdermal application (13,506.51 ± 1649.92 ng·h/mL) was ~2 times higher (p < 0.0001) as compared to oral dosage form. In conclusion, the promising results observed here signifies that developed patch could be a viable alternative for oral therapy of pioglitazone.

APA, Harvard, Vancouver, ISO, and other styles

4

Shikinami, Yasuo, Kunihiro Hata, Sumihiro Shiraishi, Kenjiro Koga, and Shigeyuki Nomura. "Colchicine transdermal tape based on polyurethane adhesive." Drug Delivery System 6, no. 6 (1991): 461–64. http://dx.doi.org/10.2745/dds.6.461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Maruo, Susumu, Hiroyoshi Minematsu, and Takeyuki Kawaguchi. "Novel Acrylic Adhesive for Transdermal Drug Delivery." Polymer Journal 32, no. 2 (February 2000): 171–72. http://dx.doi.org/10.1295/polymj.32.171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Minghetti, Paola, Francesco Cilurzo, and Antonella Casiraghi. "Measuring Adhesive Performance in Transdermal Delivery Systems." American Journal of Drug Delivery 2, no. 3 (2004): 193–206. http://dx.doi.org/10.2165/00137696-200402030-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Li-ping, Ruan, Liang Bing-weng, Tao Ji-zhi, and Yin Chim-hua. "Transdermal absorption of nitrendipine from adhesive patches." Journal of Controlled Release 20, no. 3 (August 1992): 231–36. http://dx.doi.org/10.1016/0168-3659(92)90125-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Dubey, Rupal, and Umadoss Pothuvan. "Transdermal patches: an emerging mode of drug delivery system in pulmonary arterial hypertension." Journal of Drug Delivery and Therapeutics 11, no. 4-S (August 15, 2021): 176–86. http://dx.doi.org/10.22270/jddt.v11i4-s.4925.

Full text

Abstract:

Transdermal Patches have been contributing important part to the pharmaceutical industry and medical practice by providing advances in delivery of treatment with existing and novel drugs. Transdermal drug delivery system has made great contribution in the medical practices but many researches are undergoing to achieve its full potential. Transdermal drug delivery system was came into existence to overcome difficulties of drug delivery especially oral route. Transdermal drug delivery refers to means of delivering drugs through the surface of the skin for local or systemic treatment. The drug functions after absorption through skin into the systemic circulation via capillary action at certain rate. Transdermal patches are now widely used as topical and transdermal delivery systems. These patches are a significant result of advancements in skin science, technology, and knowledge, which have been created via trial and error, clinical observation, and evidence-based investigations dating back to the earliest human records. A transdermal patch is a medicated adhesive patch that is applied to the skin and used to deliver a precise amount of medicine into the bloodstream via the skin. A benefit of transdermal medication administration over other forms of delivery systems such as oral, topical, intravenous (i.v.), intramuscular (i.m.), and so on is that it is non-invasive. Transdermal patches provide medication to the patient in a regulated manner, either by a porous membrane covering a reservoir of medication or by body heat melting tiny layers of drug contained in the adhesive. This review article covers the basics of transdermal patches, such as the many types of patches, how they're made, and what factors influence them, among other things. Keyword: Skin Delivery, Transdermal Drug Delivery System, Transdermal Excipients, Pulmonary Arterial Hypertension, Sildenafil Citrate.

APA, Harvard, Vancouver, ISO, and other styles

9

Zhang, Xiaoxuan, Guopu Chen, Yunru Yu, Lingyu Sun, and Yuanjin Zhao. "Bioinspired Adhesive and Antibacterial Microneedles for Versatile Transdermal Drug Delivery." Research 2020 (May 8, 2020): 1–9. http://dx.doi.org/10.34133/2020/3672120.

Full text

Abstract:

Microneedles have attracted increasing interest among various medical fields due to their painless, noninvasive, and efficient way of drug delivery. However, practical applications of these microneedles in different epidermal locations and environments are still restricted by their low adhesion and poor antimicrobial activity. Here, inspired by the antibacterial strategy of Paenibacillus polymyxa and adhesion mechanisms of mussel byssi and octopus tentacles, we develop hierarchical microneedles with multifunctional adhesive and antibacterial abilities. With polydopamine hydrogel as the microneedle base and a loop of suction-cup-structured concave chambers encircling each microneedle, the generated microneedles can fit the skin well; keep strong adhesion in dry, moist, and wet environments; and realize self-repair after being split into two parts. Besides, as polymyxin is loaded into both the hydrogel tips and the polydopamine base, the microneedles are endowed with excellent ability to resist common bacteria during storage and usage. We have demonstrated that these microneedles not only showed excellent adhesion when applied to knuckles and ideal antibacterial activity but also performed well in drug-sustained release and treatment for the osteoarthritis rat model. These results indicate that bioinspired multifunctional microneedles will break through the limitation of traditional methods and be ideal candidates for versatile transdermal drug delivery systems.

APA, Harvard, Vancouver, ISO, and other styles

10

Niharika and Navneet Verma. "Adhesive Polymers in Fabrication of Transdermal Drug delivery." Research Journal of Pharmacy and Technology 9, no. 7 (2016): 945. http://dx.doi.org/10.5958/0974-360x.2016.00182.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Van Buskirk, G. "Scale-up of adhesive transdermal drug delivery systems, ,." European Journal of Pharmaceutics and Biopharmaceutics 44, no. 3 (November 1997): 327–31. http://dx.doi.org/10.1016/s0939-6411(97)00138-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cronin, Carol M., Erasmo A. Mitrano, Rowena S. Wilder, Elizabeth P. Harmon, and Randall M. Zusman. "Comparative Evaluation of the Three Commercially Available Transdermal Nitroglycerin Delivery Systems." Drug Intelligence & Clinical Pharmacy 21, no. 7-8 (July 1987): 642–44. http://dx.doi.org/10.1177/1060028087021007-816.

Full text

Abstract:

We comparatively evaluated the patient preference for each of the three commercially available transdermal nitroglycerin delivery systems using a randomized crossover study design. Preference was determined by ease of application, adhesion, occurrence of local irritation at the site of application, and systemic toxicities. In addition, we recorded the number of nitroglycerin tablets taken and angina attacks reported per treatment course. Each treatment course was one month long, with each patient participating for a total of three months. This allowed all patients to be exposed to each of the three products for one treatment course, thereby serving as their own controls. Thirty-eight patients completed the three-phase crossover and expressed a preference. Results showed that Transderm-Nitro was significantly preferred over both Nitro-Dur and Nitrodisc (p < 0.005). Most of the preferences were based on cosmetic appearances or adhesive qualities. Additionally, results showed that there was no difference in efficacy among the three products when number of angina attacks reported and number of nitroglycerin tablets taken were compared.

APA, Harvard, Vancouver, ISO, and other styles

13

Verma, Anurag, Vaibhav Rastogi, Pragya Yadav, and Niharika Lal. "Aspects of Pressure Sensitive Adhesives in Fabricating Drug-in-Adhesive Transdermal Therapeutic Systems." Drug Delivery Letters 7, no. 1 (March 3, 2017): 3–15. http://dx.doi.org/10.2174/2210303107666170203123445.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Hsieh, Chin-Hsiung, Yuan-An Ku, Lien-Hua Chiu, Tai-Horng Young, and Yi-You Huang. "A TRANSDERMAL DRUG DELIVERY SYSTEM CONTAINING DEFERIOXAMINE MESYLATE FOR THE TREATMENT OF BETA-THALASSAEMIA MAJOR." Biomedical Engineering: Applications, Basis and Communications 23, no. 01 (February 2011): 29–35. http://dx.doi.org/10.4015/s1016237211002347.

Full text

Abstract:

Patients with beta-thalassaemia major need blood transfusion frequently during their whole life. However, frequent transfusions will eventually lead to the accumulation of trivalent iron, resulting in iron overload. To reduce iron overload, patients are administered regularly with intravenous or subcutaneous infusion of deferioxamine mesylate (DFO). Nevertheless, high costs of medication, poor patient compliance, and side effects limit its use and patient's acceptance. To overcome such drawbacks, we developed a novel transdermal delivery system to administer the DFO instead of traditional injections. We assayed the feasibility of fabricating a transdermal DFO patch using the single-layer drug-in-adhesive drug delivery system. We used the pressure-sensitive adhesives and hydrogels as the drug reservoirs and studied the release profile of DFO from the transdermal patches in vitro. In order to enhance the transdermal delivery rate, chemical enhancers, polysorbate 80 and oleic acid, and physical enhancer, ultrasound, were incorporated into the monolith DFO patches. Experimental results showed that the combination of polysorbate 80 and oleic acid in the pressure-sensitive adhesives enhanced the penetration efficiency through nude mice skin. The pretreatment of nude mice skin with ultrasound temporally changed the diffusional resistance and facilitated DFO penetration through the skin. We expect that the new delivery system can enable the drug to penetrate through skin at a stable rate and reach the circulation system successfully, thus allowing the concentration of drug to achieve the therapeutic effect.

APA, Harvard, Vancouver, ISO, and other styles

15

Jarenputtakrun, Ponwanit, Praneet Opanasopit, Suwannee Panomsuk, and Tanasait Ngawhirunpat. "Formulation and Evaluation of Isosorbide Dinitrate Acrylic Matrix Transdermal Patches." Advanced Materials Research 197-198 (February 2011): 1217–20. http://dx.doi.org/10.4028/www.scientific.net/amr.197-198.1217.

Full text

Abstract:

The aim of this study was to prepare and investigate the isosorbide dinitrate transdermal patches (IDPs) in the concentration of 40 mg/cm2. Acrylic pressure sensitive adhesives (PSA) were used to formulate IDPs. IDPs were prepared by casting method. The effect of content of PSA, and concentration of enhancer, propylene glycol, in the formulations were evaluated. IDPs were investigated for their thickness, weight/area ratio, adhesiveness and in vitro skin permeation. The higher the content of PSA in the formulation, the higher the thickness and the W/A ratio. Propylene glycol added in the formulation (2.5, 5, 10%) significantly enhanced the skin permeation of ISDN. The higher the content of PG, the higher the flux of ISDN through the skin. Our research suggests that isosorbide dinitrate loaded with 10% of propylene glycol in acrylic matrix pressure sensitive adhesive can be potentially used as a transdermal drug delivery system.

APA, Harvard, Vancouver, ISO, and other styles

16

Wonglertnirant, Nanthida, S. Tipwichai, Praneet Opanasopit, Theerasak Rojanarata, Suwannee Panomsuk, and Tanasait Ngawhirunpat. "Development of Acrylic Matrix Type Ketoprofen Patch." Advanced Materials Research 506 (April 2012): 533–36. http://dx.doi.org/10.4028/www.scientific.net/amr.506.533.

Full text

Abstract:

Ketoprofen transdermal patches (KTPs) were fabricated using an acrylic pressure sensitive adhesive (PSA) polymer. The influence of different factors (amount of PSA, drug content, and pressure applying on the backing membrane during preparation) on the characteristics of ketoprofen patch (thickness, W/A ratio, and adhesiveness of matrix film) and in vitro drug release behavior were investigated. The results revealed the successful fabrication and a good physical appearance of KTPs using acrylic PSA. Microscopic observations, FTIR spectra, and DSC thermograms were permitted to demonstrate that the drug was dispersed molecularly in the polymer. As the amount of PSA in the adhesive matrix was increased, the release rate of ketoprofen was decreased. Contrarily, the drug release rate was increased corresponding to the increase of ketoprofen content in the adhesive matrix. There was no significant difference in the release rate when the pressure applying on the backing membrane was varied. The kinetic of ketoprofen release from acrylic matrix type transdermal patches followed the Higuchis diffusion model.

APA, Harvard, Vancouver, ISO, and other styles

17

Regenthal, Ralf, Margarita Voskanian, Frank Baumann, Jens Teichert, Christian Brätter, Achim Aigner, and Getu Abraham. "Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation." Drug Design, Development and Therapy Volume 12 (November 2018): 3653–64. http://dx.doi.org/10.2147/dddt.s170764.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Pai, Rajesh M., Meenal S. Desai, Asph D. Babtiwale, and R. Shrivastava. "Adhesive Matrix Type Transdermal Drug Delivery System for Nitroglycerin." Drug Development and Industrial Pharmacy 20, no. 11 (January 1994): 1905–9. http://dx.doi.org/10.3109/03639049409050217.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Czech, Zbigniew, and Rafał Kurzawa. "Acrylic pressure-sensitive adhesive for transdermal drug delivery systems." Journal of Applied Polymer Science 106, no. 4 (2007): 2398–404. http://dx.doi.org/10.1002/app.26751.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Cilurzo, Francesco, Chiara G. M. Gennari, and Paola Minghetti. "Adhesive properties: a critical issue in transdermal patch development." Expert Opinion on Drug Delivery 9, no. 1 (December 16, 2011): 33–45. http://dx.doi.org/10.1517/17425247.2012.637107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Schalau, Gerald K., Robert O. Huber, Linda S. Nartker, and Xavier Thomas. "Novel silicone-based adhesive technology for transdermal therapy systems." Therapeutic Delivery 8, no. 4 (April 2017): 175–78. http://dx.doi.org/10.4155/tde-2016-0085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sood, Jatin, Bharti Sapra, and Ashok K. Tiwary. "Drug in Adhesive Transdermal Formulation of Valsartan and Nifedipine: Pharmacokinetics and Pharmacodynamics in Rats." Current Drug Therapy 14, no. 2 (August 27, 2019): 153–67. http://dx.doi.org/10.2174/1574885514666181120114635.

Full text

Abstract:

Background: The increasing complications associated with hypertension often require a combination of two or more drugs acting through different routes to counter the elevated blood pressure. Objective: The present investigation envisaged at preparing and evaluating a transdermal formulation containing gelled microemulsion drug in adhesive (DIA) patch for simultaneous systemic delivery of valsartan and nifedipine aimed at effective management of hypertension. Methods: An optimized microemulsion was prepared by using Captex® 500 (7.34% w/w), Capmul® MCM (4.24% w/w), Acrysol EL 135 (24.43% w/w), Transcutol P® (5% w/w) and water (58.9% w/w). Gelling was contributed by polyvinylpyrrolidone K 90F and polyethyleneimine where the latter also conferred skin adhesion properties to the patch. DIA patches were evaluated for in vitro drug release as well as in vivo pharmacokinetics and pharmacodynamics in rats. Results: In vitro permeation of nifedipine or valsartan from the selected DIA patch was 10.67-fold and 1.25-fold higher as compared to their aqueous dispersions. The relative bioavailability of nifedipine was 1.34 and that of valsartan was 2.18 from this DIA patch with respect to the oral administration of their aqueous suspension. Conclusion: Transdermal delivery of either drug alone was not effective in reducing methyl prednisolone acetate-induced hypertension, whereas, simultaneous transdermal delivery of both drugs from DIA patch effectively maintained systolic blood pressure at a normal level in these rats for 20 h.

APA, Harvard, Vancouver, ISO, and other styles

23

Puri, Ashana, Sonalika Bhattaccharjee, Wei Zhang, Meredith Clark, Onkar Singh, Gustavo Doncel, and Ajay Banga. "Development of a Transdermal Delivery System for Tenofovir Alafenamide, a Prodrug of Tenofovir with Potent Antiviral Activity Against HIV and HBV." Pharmaceutics 11, no. 4 (April 9, 2019): 173. http://dx.doi.org/10.3390/pharmaceutics11040173.

Full text

Abstract:

Tenofovir alafenamide (TAF) is an effective nucleotide reverse transcriptase inhibitor that is used in the treatment of HIV-1 and HBV. Currently, it is being investigated for HIV prophylaxis. Oral TAF regimens require daily intake, which hampers adherence and increases the possibility of viral resistance. Long-acting formulations would significantly reduce this problem. Therefore, the aim of this study was to develop a transdermal patch containing TAF and investigate its performance in vitro through human epidermis. Two types of TAF patches were manufactured. Transparent patches were prepared using acrylate adhesive (DURO-TAK 87-2516), and suspension patches were prepared using silicone (BIO-PSA 7-4301) and polyisobutylene (DURO-TAK 87-6908) adhesives. In vitro permeation studies were performed while using vertical Franz diffusion cells for seven days. An optimized silicone-based patch was characterized for its adhesive properties and tested for skin irritation. The acrylate-based patches, comprising 2% w/w TAF and a combination of chemical enhancers, showed a maximum flux of 0.60 ± 0.09 µg/cm2/h. However, the silicone-based patch comprising of 15% w/w TAF showed the highest permeation (7.24 ± 0.47 μg/cm2/h). This study demonstrates the feasibility of developing silicone-based transdermal patches that can deliver a therapeutically relevant dose of TAF for the control of HIV and HBV infections.

APA, Harvard, Vancouver, ISO, and other styles

24

Losenkova, Svetlana Olegovna, S. K. Kirillov, E. F. Stepanova, V. E. Novikov, S. O. Losenkova, S. K. Kirillov, E. F. Stepanova, and V. E. Novikov. "DEFINITION ADHESIVE OF PROPERTIES TRANSDERMAL OF THE PLASTER WITH MEXIDOL." I.P.Pavlov Russian Medical Biological Herald 19, no. 1 (March 15, 2011): 138. http://dx.doi.org/10.17816/pavlovj20111138-141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Sakhare, AD, KR Biyani, and SG Sudke. "Design and evaluation of adhesive type transdermal patches of carvedilol." Research Journal of Pharmacy and Technology 13, no. 10 (2020): 4941. http://dx.doi.org/10.5958/0974-360x.2020.00867.7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Ghosh, Animesh, Subham Banerjee, Santanu Kaity, and Tin Wong. "Current Pharmaceutical Design on Adhesive Based Transdermal Drug Delivery Systems." Current Pharmaceutical Design 21, no. 20 (May 27, 2015): 2771–83. http://dx.doi.org/10.2174/1381612821666150428130215.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Harrison, Lester I., Dianna J. Riedel, Jane H. Machacek, Jan K. Crowley, Charlene M. Kanniainen, J. Adele Hoglin, Tom S. Robison, and Jeff M. Zumhofe. "BIOEQUIVALENCE COMPARISON OF TWO DRUG-IN-ADHESIVE TRANSDERMAL NITROGLYCERIN PATCHES." American Journal of Therapeutics 3, no. 8 (August 1996): 580–85. http://dx.doi.org/10.1097/00045391-199608000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Ravula, Ranadheer, Anushree K. Herwadkar, Mehtab J. Abla, John Little, and Ajay K. Banga. "Formulation optimization of a drug in adhesive transdermal analgesic patch." Drug Development and Industrial Pharmacy 42, no. 6 (July 31, 2015): 862–70. http://dx.doi.org/10.3109/03639045.2015.1071832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Jain, Piyush, and Ajay K. Banga. "Inhibition of crystallization in drug-in-adhesive-type transdermal patches." International Journal of Pharmaceutics 394, no. 1-2 (July 2010): 68–74. http://dx.doi.org/10.1016/j.ijpharm.2010.04.042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Nechaeva, Yuliya. "Review of pharmacy sales of plasters and self-adhesive dressings." Remedium Journal about the Russian market of medicines and medical equipment, no. 9 (2020): 51–53. http://dx.doi.org/10.21518/1561-5936-2020-9-51-53.

Full text

Abstract:

Review of pharmacy sales of plasters and self-adhesive dressingsYuliya Nechaeva, DSM Group Plasters are essential items for any medicine cabinet at home. The plasters are currently used not only in the treatment of wounds and attachment of bandages or catheters, but also have a therapeutic (for example, analgesic, venotonic, anti-edema action, etc.) or cosmetic effect (anti-cellulite, anti-wrinkle, anti-under-eye circles effects, etc.). In addition, the transdermal route of drug administration is gaining popularity.

APA, Harvard, Vancouver, ISO, and other styles

31

Wolff, Hans-Michael, Irsan, and Kalliopi Dodou. "Investigations on the Viscoelastic Performance of Pressure Sensitive Adhesives in Drug-in-Adhesive Type Transdermal Films." Pharmaceutical Research 31, no. 8 (March 6, 2014): 2186–202. http://dx.doi.org/10.1007/s11095-014-1318-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

GEEVARGHESE, Rachel, and Satish SHIROLKAR. "Formulation and evaluation of fluvastatin sodium drug-in-adhesive transdermal system." Journal of Research in Pharmacy 24, no. 4 (July 16, 2020): 562–71. http://dx.doi.org/10.35333/jrp.2020.204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Qvist, Michael H., Ulla Hoeck, Bo Kreilgaard, Flemming Madsen, and Sven Frokjaer. "Release of chemical permeation enhancers from drug-in-adhesive transdermal patches." International Journal of Pharmaceutics 231, no. 2 (January 2002): 253–63. http://dx.doi.org/10.1016/s0378-5173(01)00893-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Lake, Yvonne, and Sylvia Pinnock. "Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch." Australian and New Zealand Journal of Obstetrics and Gynaecology 40, no. 3 (August 2000): 313–16. http://dx.doi.org/10.1111/j.1479-828x.2000.tb03341.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Cilurzo, Francesco, Paola Minghetti, Chiara G. M. Gennari, Antonella Casiraghi, and Luisa Montanari. "A novel polymethylmethacrylate hydrophilic adhesive matrix intended for transdermal patch formulations." Drug Delivery 17, no. 3 (March 8, 2010): 171–77. http://dx.doi.org/10.3109/10717541003667772.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Tipre, Dnyanesh N., and Pradeep R. Vavia. "Acrylate-based pressure sensitive adhesive in fabrication of transdermal therapeutic system." Polymers for Advanced Technologies 14, no. 7 (2003): 502–7. http://dx.doi.org/10.1002/pat.361.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Tsai, Chen-Yi, and Cheng-Chung Chang. "Auto-adhesive transdermal drug delivery patches using beetle inspired micropillar structures." Journal of Materials Chemistry B 1, no. 43 (2013): 5963. http://dx.doi.org/10.1039/c3tb20735h.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Misra, Amit, and Pramod Upadhyay. "Apparatus for preparing adhesive-dispersion transdermal patches on a laboratory scale." International Journal of Pharmaceutics 132, no. 1-2 (April 1996): 267–70. http://dx.doi.org/10.1016/0378-5173(95)04262-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Mathews, Leya Meriam. "Management of pain using transdermal patches." Asian Journal of Pharmaceutical and Clinical Research 9, no. 6 (November 1, 2016): 32. http://dx.doi.org/10.22159/ajpcr.2016.v9i6.13775.

Full text

Abstract:

Transdermal delivery is a non-invasive route of drug administration through the skin surface that can deliver the drug at a predetermined rate across the dermis to achieve a local or systemic effect. It is potentially used as an alternative to oral route of drugs and hypodermic injections. Analgesics are mostly used for various diseases as most of them are associated with severe or mild pain .The use of analgesics as a pain relief patch is now being used commonly. A transdermal analgesic or pain relief patch is a medicated adhesive patch used to relieve minor to severe pain. Currently, the patches are available for many Opioids , Non opioids analgesics. Local anesthetics and antianginal drugs. The drugs include Fentanyl, Buprenorphine ketoprofen, diclofenacepolamine , piroxicam , Capsaicin ,Nitroglycerine and Lignocaine . They are available as both matrix and reservoir patches. This review explores the various drugs used to manage pain and their route of administration in terms of frequency, complications and effects

APA, Harvard, Vancouver, ISO, and other styles

40

Gansen, P., and M. Dittgen. "Polyurethanes as self adhesive matrix for the transdermal drug delivery of testosterone." Drug Development and Industrial Pharmacy 38, no. 5 (October 19, 2011): 597–602. http://dx.doi.org/10.3109/03639045.2011.620965.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Abebe, Medhen W., Richard Appiah-Ntiamoah, and Hern Kim. "Gallic acid modified alginate self-adhesive hydrogel for strain responsive transdermal delivery." International Journal of Biological Macromolecules 163 (November 2020): 147–55. http://dx.doi.org/10.1016/j.ijbiomac.2020.06.257.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Swain, Kalpana, Satyanarayan Pattnaik, Nilufa Yeasmin, and Subrata Mallick. "Preclinical evaluation of drug in adhesive type ondansetron loaded transdermal therapeutic systems." European Journal of Drug Metabolism and Pharmacokinetics 36, no. 4 (June 29, 2011): 237–41. http://dx.doi.org/10.1007/s13318-011-0053-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Jain, Piyush, and Ajay K. Banga. "Induction and Inhibition of Crystallization in Drug-in-Adhesive-Type Transdermal Patches." Pharmaceutical Research 30, no. 2 (October 24, 2012): 562–71. http://dx.doi.org/10.1007/s11095-012-0901-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Kondapuram Parameshwar, Suvendu Kumar Sahoo, Rabinarayan Parhi, Ravi Kumar V, Ahad Ahmed kodipad, and Priyadharshini Selvaraj. "Formulation and in-vitro evaluation of a transdermal patch loaded with letrozole." International Journal of Research in Pharmaceutical Sciences 11, SPL4 (December 21, 2020): 997–1005. http://dx.doi.org/10.26452/ijrps.v11ispl4.4235.

Full text

Abstract:

The prime objective behind this investigation was to plan a Letrozole enclosed adhesive transdermal patch; since the transdermal route is an outright attractive option concerning its route, convenience and safety. Letrozole, a non-steroidal type II aromatase inhibitor, is reported for treating breast tumours and in postmenopausal women. In this study, few factors confined to formulation such as drug-in-adhesive, enhancers and amount of drug-loaded were investigated. The procedure used supposedly involves, the incarnation of the LET in phospholipids exploiting to a spray dryer. FTIR, X-RD, and DSC techniques which are used to evaluate entrapment efficiency were employed to LET spray-dried powder (LT-SDP). The molecule size, polydispersity file, and the EE were allegedly found to be 284.0 nm, 0.247 and 59.08%. On adding LT-SDP to a cream base with peppermint and olive oil as regular infiltration, the optimized formulation showed superior skin targeting in both in vitro and in vivo observations post-study.In vivo bioavailability studies showed just about four-fold increment in the plasma whereas the mean residence time and half-life were reasonably higher as compared to the LET cream in plain. The in vivo results observed remarkable patch concurrence with the plasma fixations anticipated from the in vitro infiltration. As an outpatient convenience, avoidance of gastrointestinal incompatibility provides suitability for self-administration for breast cancer prevention and treatment.

APA, Harvard, Vancouver, ISO, and other styles

45

Li, Jianwei, Jeremy J. Masso, and Stanley Rendon. "Quantitative evaluation of adhesive properties and drug-adhesive interactions for transdermal drug delivery formulations using linear solvation energy relationships." Journal of Controlled Release 82, no. 1 (July 2002): 1–16. http://dx.doi.org/10.1016/s0168-3659(02)00007-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Shi, Ge, Tianqing Liu, Zlatko Kopecki, Allison Cowin, Ivan Lee, Jing-Hong Pai, Sean E. Lowe, and Yu Lin Zhong. "A Multifunctional Wearable Device with a Graphene/Silver Nanowire Nanocomposite for Highly Sensitive Strain Sensing and Drug Delivery." C 5, no. 2 (April 4, 2019): 17. http://dx.doi.org/10.3390/c5020017.

Full text

Abstract:

Advances in wearable, highly sensitive and multifunctional strain sensors open up new opportunities for the development of wearable human interface devices for various applications such as health monitoring, smart robotics and wearable therapy. Herein, we present a simple and cost-effective method to fabricate a multifunctional strain sensor consisting of a skin-mountable dry adhesive substrate, a robust sensing component and a transdermal drug delivery system. The sensor has high piezoresisitivity to monitor real-time signals from finger bending to ulnar pulse. A transdermal drug delivery system consisting of polylactic-co-glycolic acid nanoparticles and a chitosan matrix is integrated into the sensor and is able to release the nanoparticles into the stratum corneum at a depth of ~60 µm. Our approach to the design of multifunctional strain sensors will lead to the development of cost-effective and well-integrated multifunctional wearable devices.

APA, Harvard, Vancouver, ISO, and other styles

47

Taghizadeh, Seyed Mojtaba, and Sara Bajgholi. "A New Liposomal-Drug-in-Adhesive Patch for Transdermal Delivery of Sodium Diclofenac." Journal of Biomaterials and Nanobiotechnology 02, no. 05 (2011): 576–81. http://dx.doi.org/10.4236/jbnb.2011.225069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Nesseem, Demiana I., S. F. Eid, and S. S. El-Houseny. "Development of novel transdermal self-adhesive films for tenoxicam, an anti-inflammatory drug." Life Sciences 89, no. 13-14 (September 2011): 430–38. http://dx.doi.org/10.1016/j.lfs.2011.06.026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Kotiyan, P. "Eudragits: Role as crystallization inhibitors in drug-in-adhesive transdermal systems of estradiol." European Journal of Pharmaceutics and Biopharmaceutics 52, no. 2 (September 2001): 173–80. http://dx.doi.org/10.1016/s0939-6411(01)00174-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Guyot, M., and F. Fawaz. "Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol." International Journal of Pharmaceutics 204, no. 1-2 (June 2000): 171–82. http://dx.doi.org/10.1016/s0378-5173(00)00494-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!